Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Inclusion Criteria: * Histologically confirmed HNSCC with surgically resectable disease * No prior chemotherapy or radiation therapy as treatment for the observed HNSCC * Patients must provide written informed consent * Age \>=18 years of age * Eastern Cooperative Oncology Group (ECOG) Performance Status score of \<2 * Normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below: * Hemoglobin \>= 10 g/dL and no blood transfusions in the 28 days prior to entry/randomization * Absolute neutrophil count \>=1.5 x 10\^9/L * No features suggesting of MDS/AML on peripheral blood smear * White blood cells \> 3 x 10\^9/L * Platelet count \>= 100 x 10\^9/L * Total bilirubin \<= 1.5 x institutional upper limit of normal (ULN) * AST (SGOT)/ALT (SGPT) \< 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be \< 5x ULN * Serum creatinine \<= 1.5 x institutional ULN OR creatinine clearance \>= 50 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of the study participation and must have negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial * Must be abler to understand and sign a written informed consent document Exclusion Criteria: * Patients with known brain metastases. Patients may have received WBRT within 14 days or focal radiation within 1 week of cycle 1, day 1. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 28 days prior to treatment * Women must not be pregnant or breastfeeding * Patients with known hypersensitivity to olaparib or any of the excipients of the product * Patients receiving any other investigational agents within 4 weeks of starting the study * Involvement in the planning and/or conduct of the study * Any previous treatment with a PARP inhibitor, including olaparib * Concomitant use of known CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin, and nelfinavir * Persistent toxicities (\>=CTCAE grade 2) * Resting ECG with QTC \>470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome * Blood transfusions within 1 month prior to study start * Patients with myelodysplastic syndrome/acute myeloid leukemia * Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery * Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. * Unable to swallow oral medication * Immunocompromised patients, e.g., patients who are known to be serologically positive for HIV and are receiving antiviral therapy * Known active hepatic disease * Uncontrolled seizures * Previous cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for 5 years * Currently on warfarin(subcutaneous heparin is permitted)